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To inform clinical guidelines and patient care we need high quality evidence on the relative benefits and harms of
intervention. Patient reported outcome (PRO) data from clinical trials can “empower patients to make decisions
based on their values” and “level the playing field between physician and patient”. While clinicians have a good
understanding of the concept of health-related quality of life and other PROs, evidence suggests that many do not
feel comfortable in using the data from trials to inform discussions with patients and clinical practice. This may in
part reflect concerns over the integrity of the data and difficulties in interpreting the results arising from poor
reporting.
The new CONSORT PRO extension aims to improve the reporting of PROs in trials to facilitate the use of results to
inform clinical practice and health policy. While the CONSORT PRO extension is an important first step in the
process, we need broader engagement with the guidance to facilitate optimal reporting and maximize use of PRO
data in a clinical setting. Endorsement by journal editors, authors and peer reviewers are crucial steps. Improved
design, implementation and transparent reporting of PROs in clinical trials are necessary to provide high quality
evidence to inform evidence synthesis and clinical practice guidelines.
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Randomized controlled clinical trials (RCTs) can provide
high-quality data regarding the impact of study interven-
tions on patient outcomes, and remain the ‘gold stand-
ard’ of evidence regarding both the benefits and harms
associated with an intervention. Over the last twenty
years, the number of clinical trials that assess patient re-
ported outcomes (PROs) has substantially increased [1].
PROs can be defined as a “measurement of any aspect of
a patient’s health status that comes directly from the pa-
tient (i.e. without the interpretation of the patient’s re-
sponses by a physician or anyone else” [2] and include
health-related quality of life (HRQL), symptoms, satisfac-
tion and adherence to medication. These subjective mea-
sures of outcome help evaluate the burden of disease* Correspondence: f.efficace@gimema.it
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reproduction in any medium, provided the orand treatment from the patients’ perspective. In the con-
ceptual framework developed by Till and colleagues
adapted in (Figure 1) [3], PRO data from clinical trials
may directly inform patients and practitioners, or may
indirectly inform clinical practice through evidence syn-
thesis into clinical practice guidelines.
The quality of data, including PROs, from trials may be
threatened by the trial design, execution, and reporting.
Like any other outcome being considered, PROs should be
pre-specified, relevant and appropriate measure(s) [4]. Fail-
ure to address a number of specific issues at the time of
protocol writing or in the final trial report, such as the PRO
hypothesis, timing and mode of assessment and strategies
to manage missing data, can undermine the clinical validity
of findings and limit translation of these into clinical prac-
tice [5].
All RCT outcomes, including PROs, should be com-
pletely and transparently reported. Anything less may di-
minish the usability of the trial results by clinicians and
is an inefficient use of resources. High-quality reportingLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Model for the use of PRO data to inform patient care. Major routes are indicated by solid arrows whilst other possible routes are
indicated by unfilled arrows. The potential impact of the CONSORT PRO Extension on evidence from clinical trials and links to guideline
development are indicated. Adapted from Till et al. [3].
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assess the validity of the PRO findings and assess any
potential sources of bias. Evidence suggests, however,
that reporting of PROs remains sub-optimal across RCTs
[6,7]. Previous studies estimating the proportion of
PRO-RCTs that were likely to robustly inform clinical
decision-makings in prostate cancer, for example, have
found that only one third of PRO-RCTs published be-
tween 1980 and 2001 did so [8].
In a review of 794 RCTs published up to 2008 across a
range of clinical settings, only 56% of articles provided a
rationale for the selected PRO, 50% provided a PRO hy-
pothesis, 28% provided information about PRO missing
data and 64% discussed the PRO findings in the context
of the other trial outcomes [7]. Although the PROs of
some RCTs were reported in an expanded supplemen-
tary publication, this only occurred for 15% of trials at
the time of review, and the detailed PRO publications
often appeared in methodologically focused journals. In
cancer RCTs methodological drawbacks have often ham-
pered a critical appraisal of results [9,10].
Additional qualitative evidence suggests that these pat-
terns of PRO reporting negatively impact on the effective
use and dissemination of RCT PRO findings to clinical
practice. A study of 30 academic oncologists examining
their attitudes and behaviors regarding HRQL data from
clinical trials indicated that, while these data were typic-
ally valued by clinicians and felt to benefit their patients,
problems with the manner in which these data were re-
ported in the literature limited their use in clinical prac-
tice [5]. The data were considered to be less accessible
than outcomes such as survival or the adverse effects of
treatment. Many clinicians felt that HRQL/PRO data
were frequently reported in a manner that is difficult tointerpret and integrate with clinical outcomes, and were
often reported months or years after the primary trial
publication. Clinicians also wanted to be assured that
the appropriate measurement instrument was used, that
the results were not biased by missing data, that results
were not “cherry picked” (i.e., chance findings arising
from multiple testing), and that reported changes in
PROs were clinically meaningful.
In this paper, we focus on how the recently developed
CONSORT (Consolidated Standards of Reporting Trials)
PRO extension [11] may be implemented to inform indi-
vidual patient care and clinical guidelines as illustrated
in (Figure 1).The CONSORT PRO extension as a vehicle for change and
challenges to its implementation
The CONSORT statement aims to encourage transparent
and complete reporting of clinical trials and is associated
with improved reporting of trials [12]. Importantly, the
CONSORT group has a proven ability to reach consensus
on reporting guidelines and to promote their successful im-
plementation. Extensions to the original CONSORT state-
ment have provided guidance for specific trial designs,
interventions, and specific outcomes but until recently did
not provide specific guidance for PROs [13]. Such guidance
was clearly required since multiple factors threaten the
quality of PRO reporting: researchers must design their
RCTs with appropriate PRO implementation and execu-
tion, and authors must find a balance between providing
sufficient detail to adequately report PRO results within the
context of other study outcomes while still adhering to
journal requirements for manuscript length and structure.
Reviewers and editors must find the optimal balance
Calvert et al. Health and Quality of Life Outcomes 2013, 11:184 Page 3 of 7
http://www.hqlo.com/content/11/1/184between demanding that certain reporting standards be in-
cluded in the context of the same journal constraints.
The development of a CONSORT PRO extension was
thus undertaken, led by a Task Force of the International
Society for Quality of Life Research (ISOQOL) and
guided by the methodological framework proposed by
the EQUATOR Network [14]. Briefly, a systematic
search was used to identify candidate reporting stan-
dards for PROs [15]. An electronic survey of stakeholder
groups was used to obtain experts’ judgments of the im-
portance of each candidate standard for PRO reporting
and the survey results were then debated by a face-to-
face meeting of stakeholders to achieve consensus on
items that should comprise a CONSORT extension. The
meeting agenda included: a review of relevant evidence,
discussion of the rationale for including or excluding
items in a PRO reporting standards checklist from the
point of view of the multiple stakeholders at the table,
anonymous voting on the proposed standards, the devel-
opment of a draft CONSORT extension, and the devel-
opment of a knowledge translation and dissemination
strategy [13,14].
The group was ultimately able to reach consensus on
five “extension” statements to the 2010 CONSORT guid-
ance that each address a key reporting item considered
critical for quality reporting from all types of RCTs
where PROs are a primary or “important” secondary
outcome as shown in Table 1. Important secondary out-
comes refer to pre-specified domains that are focus ofTable 1 Summary of the CONSORT PRO extension items
CONSORT 2010 statement PRO extensio
Structured summary of trial design,
methods, results, and conclusions
The PRO should be identified in
primary or secondary outcome
Specific objectives or hypotheses The PRO hypothesis should be s
domains identified, if applicable
Completely defined pre-specified primary
and secondary outcome measures,
including how and when they were
assessed.
Evidence of PRO Instrument vali
should be provided or cited if a
the person completing the PRO
data collection (paper telephone
Statistical Methods used to compare
groups for primary and secondary
outcomes
Statistical approaches for dealin
are explicitly stated.
Trial limitations addressing sources of
potential bias, imprecision, and, if relevant
multiplicity of analyses
PRO-specific limitations and imp
generalizability and clinical prac
discussed.
Generalizability (external validity,
applicability) of trial findings
Authors are referred to the CONSORT PRO Extension paper for further explanation
conjunction with the CONSORT checklist and relevant extensions as appropriate forthe principal PRO analyses [11]. In addition, critical
components of the existing 2010 CONSORT guidance
that were critically relevant to PRO reporting were ex-
panded by “elaboration” statements. The rationale for
each of the 5 items comprising the CONSORT PRO ex-
tension are briefly summarized in Table 1. Readers are
referred to the CONSORT PRO Extension for further
information on the rationale for each item, examples of
reporting and elaboration of the existing CONSORT
2010 statement in relation to PROs [11]. These guidance
statements, if implemented by authors and journal re-
viewers/editors, could potentially improve reporting and
facilitate interpretation of PRO results for use in clinical
practice.
Experience with the CONSORT Statement suggests
that efforts to implement the CONSORT PRO Extension
will face a number of challenges. First and foremost is
obtaining journal endorsement for the CONSORT PRO
Extension. A 2008 analysis of “Instructions to Authors”
for 165 high impact factor medical journals found that
only 38% mentioned the main CONSORT statement in
their online instructions [16]. Moreover, of the four
CONSORT extensions that were examined, no single ex-
tension was mentioned on more than 3% of journal web-
sites. Evidence suggests that reporting is improved in
those journals with a policy of active implementation of
CONSORT [17].
Theory and research on dissemination and implemen-
tation in health care settings suggests ways to promoten Brief rationale for extension
the abstract as a Explicitly identifying PROs in the RCT abstract will
facilitate indexing and identification of studies to
inform clinical care and evidence synthesis.
tated and relevant
.
PRO measures may be multi-dimensional and may
assess patient status at several time points during
a RCT. A pre-specified hypothesis reduces the risk
of multiple statistical testing and selective






This information will allow readers to assess the
validity, reliability and appropriateness of the PRO
being used.
g with missing data Missing PRO data is a potential source of bias. A
number of methods for dealing with missing data
are available with different strengths and




PRO specific limitations may influence the
generalizability of results and use in clinical
practice.
and the full list of items [11]. The CONSORT PRO extension should be used in
the study design.
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tensions [18]. Success can be enhanced when efforts ex-
tend beyond typical “push” approaches (i.e., publishing
and publicizing new information), to include “pull” ap-
proaches (i.e., creating demand for change among the
target audience). One possible way to create demand for
endorsement is to have regular public reporting audit of
those journals that do and do not mention CONSORT
or its extensions in their online Instructions to Authors.
Even when CONSORT is endorsed there is considerable
variation in how it is implemented at journals. Without
strong direct language, for example, in a journal’s Instruc-
tions to Authors section, prospective authors will not have
clear guidance about how they need to comply with journal
endorsement. Plans to develop online resources which pro-
vide specific examples taken from publications should fa-
cilitate adherence to the new CONSORT-PRO checklist.
Problems may be encountered; however, with consistency
in the operationalization of “important secondary out-
comes” since this term is not currently part of the standard
clinical trial lexicon. In addition, problems may be encoun-
tered with how authors interpret the requirement that evi-
dence of PRO instrument reliability or validity be provided
or cited if available. Several questions arise in this regard. Is
it sufficient to cite the original article that describes an in-
strument’s psychometric properties? Ideally further infor-
mation on reliability should be reported in relation to the
population of study in the clinical trial. Should supporting
evidence also be provided for an instrument’s responsive-
ness to change? Should additional psychometric informa-
tion be provided for translations of instruments? In
addressing these issues, authors will need to stay abreast of
evolving standards for PROs and their use in clinical re-
search [2,19].Table 2 Level of reporting in recently conducted prostate can
according to the new CONOSRT PRO extension
Consort 2010 statement PRO extension
Structured summary of trial design, methods,
results, and conclusions
The PRO should be identi
or secondary outcome
Specific objectives or hypotheses
The PRO hypothesis shou
domains identified, if app
Completely defined pre-specified primary and
secondary outcome measures, including how
and when they were assessed.
Evidence of PRO Instrume
be provided or cited if av
completing the PRO and
(paper telephone electron
Statistical Methods used to compare groups for
primary and secondary outcomes
Statistical approaches for
explicitly stated.
Trial limitations addressing sources of potential
bias, imprecision, and, if relevant multiplicity of
analyses PRO-specific limitations an
and clinical practice shou
Generalizability (external validity, applicability) of
trial findings
Data extracted from Efficace et al. [20].Potential impact of the CONSORT PRO extension on the
quality of clinical trial reporting
The need for improvement in the reporting of PROs is one
of the principal reasons for developing the CONSORT
PRO Extension. How likely is it, however, that publication
and implementation of the CONSORT PRO Extension will
have the desired positive impact? A recent systematic re-
view and meta-analysis provides some insight. The review
encompassed published studies evaluating the complete-
ness of reporting of randomized controlled trials in medical
journals based on CONSORT Statement criteria [12]. Data
for the review were drawn from 53 publications encom-
passing over 16,000 randomized clinical trials. Findings
showed that 25 of 27 comparisons of the completeness of
reporting favored CONSORT-endorsing journals over non-
endorsers, with five of these comparisons yielding statisti-
cally significant differences. These findings strongly suggest
that endorsement of the CONSORT PRO Extension will
over time result in improvements in the reporting of PROs
in clinical trials.
A Real-World Example from Oncology: evidence from
prostate cancer RCTs evaluated against the CONSORT
PRO extension items
In an effort to provide current evidence on the level of
reporting according to the new CONSORT PRO exten-
sion items, in Table 2 we provide the proportion of re-
cently conducted PRO-RCTs in prostate cancers that
have addressed such issues. A systematic literature
search, identifying all RCTs published with a PRO com-
ponent (published between 2004 and 2012) in prostate
cancers found 65 studies [20]. All these RCTs were scru-
tinized based on a number of methodological criteria,
including the CONSORT PRO extension items and datacer RCTs (65 studies published between 2004 and 2012)
Level of reporting, n (%)
fied in the abstract as a primary
59/65 (91%)
ld be stated and relevant
licable.
24/65 (37%)
nt validity and reliability should
ailable including the person
methods of data collection
ic other).
43/65 (66%), Yes, for all PRO
instruments used in the study.
15/65 (23%), reported “mode of
administration”
dealing with missing data are
12/65 (18%)
d implications for generalizability
ld be discussed.
23/65 (35%) PRO-specific limitations
discussed.
37/65 (57%) Implications for
generalizability
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only 18% of studies documented statistical methods for
addressing PRO missing data. Also, only 23% reported
methods for PRO administration. These very low per-
centages, underscore that some specific items reported
in the new CONSORT PRO extension, are in urgent
need of improvement to raise confidence in the solidity
of PRO data stemming from these RCTs.Implications of the CONSORT PRO extension for RCT
design
The CONSORT PRO extension has important implications
for trial design, although design decisions may go beyond
simply what should be reported. The problem of PRO
missing data illustrates this distinction. Difficulties with
PRO data collection and compliance have historically been
considered the major barriers to the successful implemen-
tation of PRO in clinical trials [21]. The CONSORT PRO
extension states that the amount of missing data and way
that this has been addressed in the analysis should be re-
ported. The analysis plan should clearly be pre-specified at
the design stage, but in addition methods to prevent or
minimize missing data in the trial should be stated. In
addition the CONSORT PRO Extension stipulates that evi-
dence of PRO instrument validity and reliability be included
as part of the manuscript submission. This criterion has the
potential to foster greater consideration of a PRO measure’s
psychometric properties at the time of protocol design,
thereby promoting greater use of measures with demon-
strated reliability and validity. Likewise, consider the CON-
SORT PRO Extension item stipulating that the PRO
hypothesis be stated in the manuscript, with relevant do-
mains identified if applicable. This criterion has the poten-
tial to foster greater pre-specification of PRO hypotheses at
the time of protocol development, thereby reducing the
likelihood of selective reporting of PRO results in manu-
script. It should be noted, however, that specification of
outcomes in a protocol may not be sufficient to eliminate
the problem of selective result reporting. Indeed, an audit
comparing protocols submitted to a leading medical journal
and the published reports based on those protocols found
numerous discrepancies between the pre-specified out-
comes and the reported outcomes [22]. Additional efforts,
such as providing manuscript reviewers with access to the
original protocols, would appear to be necessary to mean-
ingfully address the issue of selective reporting.
Within this framework, it is possible to envisage a
positive impact of endorsement of the CONSORT
PRO Extension not only in improving to the quality
of clinical trial reporting but also on PRO trial de-
sign. The quality of certain aspects of clinical trials
incorporating PROs are likely to improve as a direct
result of widespread adoption of the CONSORTPRO Extension, while others will require more
multi-faceted efforts on the part of the research
community.
Improved PRO trial design and reporting: implications for
guideline development
Individual randomized trials may either by chance or
as a result of bias not represent the best possible esti-
mates of an effect of an intervention on PROs. Thus,
single small RCTs are rarely informative for evidence
based health care decisions. Evidence-based health
care decisions require systematic reviews to more
completely consider the possible influence of bias and
chance on health care decisions.
Systematic reviews of intervention effects alone,
however, are also insufficient for evidence-based
health care decision-making. In addition to informa-
tion about effects of interventions, health care deci-
sions require consideration of issues around the
clinical state and circumstances including baseline
risks for a certain outcome, the populations and soci-
etal values and preferences, estimates of effect and
expertise to bring all of that together. Practice guide-
lines are recommendations that are intended to assist
providers, recipients of health care and other stake-
holders to make informed decisions and can take on
the role of adequate support tools [23].
PROs can inform evidence-based recommendations
in a number of ways. PROs address what matters to
patients and their use in clinical trials can provide
the information that is critical for decision making in
practice guidelines. PROs also can provide informa-
tion about the importance of other outcomes, non
PROs, by conducting explicit value and preference
elicitation exercises. Transparent communication of
both the confidence in an estimate of effect on a
PRO, which is also called the quality of the evidence
[24,25], and the estimate itself remains challenging.
The GRADE Working Group has developed a system
to assess the confidence and the likelihood of an esti-
mate of effect on PRO that facilitates communication,
which may be incorporated formally in the review
process. The group is now focusing on a structured
approach to assessing the confidence in estimates of
values and preferences that influence the development
of health care recommendations. The system is used
by over 70 organizations worldwide. Using such sys-
tems has become a requirement in most standards on
clinical practice guideline development [26,27].
Conclusion
In conclusion, robust methodology and accurate
reporting of data are crucial when evaluating PROs in
clinical trials in order to provide health care providers
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the impact of a given drug or a novel therapeutic ap-
proach on the patient’s health status. Scientific publi-
cations stemming from a poor study design or simply
reporting insufficient information can mislead readers
when interpreting study outcomes. Such publications
are wasteful, both in terms of opportunities for pro-
viding better evidence, research funding, the effort of
everyone involved from concept to paper – including
but not confined to investigators, ethics committees,
patients, trial co-ordinators, statisticians, journal staff,
reviewers and finally readers. The new CONSORT
PRO extension aims to raise quality standards and
help bridge the gap between PRO-trial based out-
comes and clinical practice by increasing clinician
confidence in published PRO evidence.
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